|
| Status |
Public on May 31, 2023 |
| Title |
EZH2 inhibtion and IFNy treatment of patient derived organoids |
| Organisms |
Homo sapiens; Mus musculus |
| Experiment type |
Expression profiling by high throughput sequencing
Genome binding/occupancy profiling by high throughput sequencing
|
| Summary |
This SuperSeries is composed of the SubSeries listed below.
|
| |
|
| Overall design |
Refer to individual Series
|
| |
|
| Citation(s) |
37333199, 38265267 |
| |
| Submission date |
May 25, 2023 |
| Last update date |
Feb 26, 2024 |
| Contact name |
Jinpeng Liu |
| Organization name |
Markey Cancer Center
|
| Street address |
800 Rose St
|
| City |
Lexington |
| State/province |
Kentucky |
| ZIP/Postal code |
40536 |
| Country |
USA |
| |
|
| Platforms (5)
|
| GPL21273 |
HiSeq X Ten (Mus musculus) |
| GPL24247 |
Illumina NovaSeq 6000 (Mus musculus) |
| GPL24676 |
Illumina NovaSeq 6000 (Homo sapiens) |
|
| Samples (54)
|
|
| This SuperSeries is composed of the following SubSeries: |
| GSE233468 |
EZH2 inhibtion and IFNy treatment of patient derived organoids [RNA-seq] |
| GSE233469 |
EZH2 inhibtion and IFNy treatment of patient derived organoids [ChIP-seq] |
| GSE233665 |
EZH2 inhibtion and IFNy treatment of patient derived organoids [scRNA-Seq] |
|
| Relations |
| BioProject |
PRJNA976305 |
Less...
More...